咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >HER2 heterogeneity in gastric/... 收藏

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice

作     者:Federica Grillo Matteo Fassan Francesca Sarocchi Roberto Fiocca Luca Mastracci 

作者机构:Department of Surgical and Diagnostic Sciences Pathology Unit University of Genoa 16132 Genoa Italy Institute for Research and Cure of Cancer (IRCCS) S. Martino-IST University Hospital 16132 Genoa Italy Department of Medicine (DIMED) Surgical Pathology Unit University of Padua 35121 Padua Italy 

出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))

年 卷 期:2016年第22卷第26期

页      面:5879-5887页

核心收录:

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Gastric cancer HER2 Heterogeneity Immunohistochemistry FISH 

摘      要:HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focuses on HER2 in gastric carcinogenesis, on optimal evaluation of HER2 and on the possible causes which may contribute to inaccurate HER2 evaluation. Similarly to breast cancer HER2 evaluation, standardization of HER2 testing in gastric cancer is necessary in diagnostic practice. The three principle aspects which require consideration are:(1) the choice of sample with regards to cancer morphology- intestinal vs diffuse areas;(2) the choice of scoring criteria- use of HER2 scoring criteria specific for gastric cancer; and(3) the choice of HER2 evaluation methods- use of an algorithm in which both immunohistochemistry and in situ hybridization play a role. Problematic issues include:(1) pre-analytic variables with particular emphasis on fixation;(2) recommended methodology for HER2 assessment(immunohistochemistry vs in situ hybridization);(3) HER2 heterogeneity both within the primary tumor and between primary tumor and metastases;(4) reliability of biopsies in HER 2 evaluation; and(5) quantity of sample(FFPE blocks from surgical specimens or endoscopic biopsies) necessary for an adequate assessment.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分